Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Pfizer
This is a Phase 2, China only, multi center, open label, dual cohort study, in ALK positive locally advanced or metastatic NSCLC patients will be enrolled to receive lorlatinib monotherapy. * (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor. * (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted